|
STAU1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.22889999684983E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.44790000000672E-06 |
| Normal-vs-Stage2 |
3.602200E-03 |
| Normal-vs-Stage3 |
2.37889996590468E-09 |
| Normal-vs-Stage4 |
9.70820000000261E-05 |
| Stage1-vs-Stage2 |
4.004800E-01 |
| Stage1-vs-Stage3 |
3.404300E-02 |
| Stage1-vs-Stage4 |
7.234800E-01 |
| Stage2-vs-Stage3 |
2.304300E-02 |
| Stage2-vs-Stage4 |
3.290400E-01 |
| Stage3-vs-Stage4 |
2.653400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.28459997983788E-09 |
| Normal-vs-AfricanAmerican |
1.296440E-01 |
| Normal-vs-Asian |
1.963360E-04 |
| Caucasian-vs-AfricanAmerican |
2.129900E-02 |
| Caucasian-vs-Asian |
5.872800E-01 |
| AfricanAmerican-vs-Asian |
1.044360E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.30599999999637E-05 |
| Normal-vs-Female |
3.2944999950324E-08 |
| Male-vs-Female |
3.808200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.17129999999988E-05 |
| Normal-vs-Age(41-60Yrs) |
2.16030000554923E-08 |
| Normal-vs-Age(61-80Yrs) |
1.34269999996217E-06 |
| Normal-vs-Age(81-100Yrs) |
1.019960E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.607790E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.930800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.735200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.397200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.937600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.219800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.832000E-02 |
| Classical-VS-Follicular |
1.863190E-01 |
| Classical-VS-Other |
4.892400E-01 |
| Classical-VS-Normal |
1.16269999961283E-07 |
| Tall-VS-Follicular |
1.523540E-02 |
| Tall-VS-Other |
9.520200E-01 |
| Tall-VS-Normal |
5.41669999964967E-07 |
| Follicular-VS-Other |
3.260200E-01 |
| Follicular-VS-Normal |
2.900300E-03 |
| Other-VS-Normal |
1.566120E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.96070000036653E-07 |
| Normal-vs-N1 |
1.56749999979944E-07 |
| N0-vs-N1 |
5.280500E-02 |
|
|
